Primary care physician opinion survey on FDA Opioid Risk Evaluation and Mitigation Strategies

Journal of Opioid Management

Volumn 7, Issue 2, 2011, Pages 109-115

  Slevin, Kieran A ^a   Ashburn, Michael A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breakthrough pain; Opioids; Regulation

Indexed keywords

OPIATE;

ARTICLE; CANCER PAIN; DRUG ABUSE; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTICE; HEALTH PRACTITIONER; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; PAIN; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PRESCRIPTION; PRIMARY MEDICAL CARE; PROFESSIONAL PRACTICE; RISK ASSESSMENT;

ANALGESICS, OPIOID; HUMANS; LEGISLATION, DRUG; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, PRIMARY CARE; RISK ASSESSMENT; RISK MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955931440     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0053     Document Type: Article

References (11)

1. Leong M, Murnion B, Haber PS: Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J. 2009; 39: 676-681.
2. Paulozzi LJ, Budnitz DS, Xi Y: Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006; 15: 618-627. (Pubitemid 44404658)
3. Kuehn BM: Efforts aim to curb opioid deaths, injuries. JAMA. 2009; 301: 1213-1215.
4. Meyer BM: The Food and Drug Administration Amendments Act of 2007: Drug safety and health-system pharmacy implica tions. Am J Health Syst Pharm. 2009; 66: S3-S5.
5. Shane R: Risk evaluation and mitigation strategies: Impact on patients, health care providers, and health systems. Am J Health Syst Pharm. 2009; 66: S6-S12.
6. FDA Website: Questions and answers about Onsolis (fentanyl buccal soluble film). Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm172039.htm. Accessed July 28, 2009.
7. Baron RJ: What's keeping us so busy in primary care? A snapshot from one practice. N Engl J Med. 2010; 362: 1632-1636.
8. Tompkins DA, Lanier RK, Harrison JA, et al.: Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology (Berl). 2010; 210: 471-480.
9. Butler SF, Black R, Grimes Serrano JM, et al.: Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. Pain Med. 2010; 11: 81-91.
10. White AG, Birnbaum HG, Schiller M, et al.: Analytic models to identify patients at risk for prescription opioid abuse. Am J Manag Care. 2009; 15: 897-906.
11. Wilsey BL, Fishman SM, Casamalhuapa C, et al.: Documenting and improving opioid treatment: The Prescription Opioid Documentation and Surveillance (PODS) System. Pain Med. 2009; 10: 866-877.